Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Donna Armentano is active.

Publication


Featured researches published by Donna Armentano.


Human Gene Therapy Methods | 2013

Generation and Characterization of Adeno-Associated Virus Producer Cell Lines for Research and Preclinical Vector Production

John Martin; Amy Frederick; Yuxia Luo; Robert Jackson; Michelle Joubert; Bruce Sol; Francis Poulin; Eric Pastor; Donna Armentano; Samuel C. Wadsworth; Karen A. Vincent

Adeno-associated virus (AAV) producer cell lines represent an effective method for large-scale production of AAV vectors. We set out to evaluate and characterize the use of an abbreviated protocol to generate masterwells (MWs; a nonclonal cell population) as a platform for research and preclinical vector production. In this system, a single plasmid containing three components, the vector sequence, the AAV rep, and cap genes, and a selectable marker gene is stably transfected into HeLaS3 cells. Producer cell lines generating an AAV2 vector expressing a secreted form of human placental alkaline phosphatase (SEAP) have been created. Several MWs showed vector yields in the 5×10(4) to 2×10(5) DNase-resistant particles/cell range, and the productivity was stable over >60 population doublings. Integrated plasmid copy number in three high-producing MWs ranged from approximately 12 to 50; copies were arranged in a head-to-tail configuration. Upon infection with adenovirus, rep/cap copy number was amplified approximately 100-fold and high yield appeared to be dependent on the extent of amplification. Rep/cap gene expression and vector packaging both reached a peak at 48u2009hr postinfection. AAV2-SEAP vector was produced in 1-liter shaker culture and purified for assessment of vector quality and potency. The data showed that the majority of the capsids from the MWs contained vector DNA (≥70%) and that purified vector was free of replication-competent AAV. In vitro and in vivo analyses demonstrated that potency of the producer cell-derived vector was comparable to vector generated via the standard transfection method.


Gastroenterology | 1995

Correction of the cystic fibrosis defect by gene complementation in human intrahepatic biliary epithelial cell lines

Shelley A. Grubman; Shaona L. Fang; Andrew E. Mulberg; Ronald D. Perrone; Linda C. Rogers; D. W. Lee; Donna Armentano; Sandra L. Murray; Henry L. Dorkin; Seng H. Cheng; Alan Smith; Douglas M. Jefferson

BACKGROUND/AIMSnHepatobiliary disease is the second most common cause of mortality in patients with cystic fibrosis (CF). In the liver, only the intrahepatic biliary epithelial (IBE) cells express cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel. The aim of this study was to determine whether human CF-derived IBE cells can be infected with adenovirus and the CF phenotype complemented.nnnMETHODSnIBE cells were isolated from 2 patients with CF and immortalized using retrovirus transduction of SV40 large T antigen. Immortalized cells were infected with the adenovirus vector Ad2/CFTR2 and assayed 2-31 days postinfection for cyclic adenosine monophosphate (cAMP)-induced halide efflux. Halide efflux was measured in single cells using fluorescence microscopy and the fluorescent probe 6-methoxy-N-(3-sulfopropyl)-quinolinium.nnnRESULTSnCF-derived IBE cell lines express biliary specific markers and express no cAMP-inducible halide efflux. Following infection with the adenovirus vector Ad2/CFTR2, a cAMP-induced halide efflux was observed for 31 days, although the number of responsive cells decreased with time.nnnCONCLUSIONSnHuman CF-IBE cells can be infected by adenovirus and the defective CFTR complemented. The loss of responsive cells with time could be due to loss of construct and/or a reduced growth of cells that are overexpressing CFTR. These CF-IBE cell lines offer an opportunity to determine the mechanisms responsible for hepatobiliary disease in the patients with CF.


Human Gene Therapy | 1999

Increased Duration of Transgene Expression in the Lung with Plasmid DNA Vectors Harboring Adenovirus E4 Open Reading Frame 3

Nelson S. Yew; John Marshall; Malgorzata Przybylska; Donna M. Wysokenski; Robin J. Ziegler; Patrick W. Rafter; Chester Li; Donna Armentano; Seng H. Cheng

For gene therapy to be effective in the treatment of chronic diseases, plasmid DNA (pDNA) vectors that provide persistent expression of therapeutic levels of the transgene product are desirable. Studies in the lung with adenovirus vectors showed that products of the adenovirus E4 region can act both in cis and in trans to increase the duration of expression when transcription of the transgene was under the control of the human cytomegalovirus (CMV) promoter. To determine if these E4-encoded proteins could also effect greater persistence of expression from a nonviral vector, a complex composed of cationic lipid GL-67, a CMV promoter plasmid (pCF1-CAT), and an E4-containing adenovirus vector (Ad2/betagal-4) was instilled into the lungs of BALB/c nu/nu mice. Significant increases in the duration of transgene expression were observed for up to 10 weeks postinstillation compared with expression from mice instilled with control complexes containing an adenovirus vector deleted of most of E4 (Ad2/betagal-2). This effect could also be observed in immunodeficient NIH-rnu rats as well as in immunocompetent BALB/c mice. Studies with CMV promoter mutants indicated that a region proximal to the promoter was necessary for the E4-mediated increase in longevity of expression. In addition to the CMV promoter, a CMV enhancer-human mucin I (MUC-I) hybrid promoter also responded to these E4-encoded proteins with increased persistence of transgene expression, but a human interleukin 8 (IL-8) promoter did not. Ad2/betagal-4 could be replaced by a pDNA vector expressing only the E4 region, indicating that products of the E4 region alone were sufficient in the absence of expression from the rest of the adenovirus genome. Further analysis indicated that the protein encoded by open reading frame 3 (ORF3) alone was sufficient for conferring the increase in persistence of expression. These data indicate that expression of a single protein from the adenovirus genome can significantly improve the duration of transgene expression from pDNA vectors, and increases the feasibility of using nonviral vectors for the treatment of chronic diseases.


Human Gene Therapy | 1993

Development and analysis of recombinant adenoviruses for gene therapy of cystic fibrosis

Devra P. Rich; Larry A. Couture; Lisa M. Cardoza; Vicki M. Guiggio; Donna Armentano; Pearl C. Espino; Kathleen M. Hehir; Michael Welsh; Alan E. Smith; Richard J. Gregory


Human Gene Therapy | 1995

Characterization of an Adenovirus Gene Transfer Vector Containing an E4 Deletion

Donna Armentano; Cathleen Sookdeo; Kathleen M. Hehir; Richard J. Gregory; Judith A. St. George; Gregory A. Prince; Samuel C. Wadsworth; Alan E. Smith


Human Gene Therapy | 1997

Characterization of Factors Involved in Modulating Persistence of Transgene Expression from Recombinant Adenovirus in the Mouse Lung

Johanne Kaplan; Donna Armentano; Tim E. Sparer; Susan G. Wynn; Pamela A. Peterson; Samuel C. Wadsworth; Kristen K. Couture; Sarah E. Pennington; Judith A. St. George; Linda R. Gooding; Alan E. Smith


Comparative Medicine | 2011

STR/ort Mice, a Model for Spontaneous Osteoarthritis, Exhibit Elevated Levels of Both Local and Systemic Inflammatory Markers

Sirkka Kyostio-Moore; Bindu Nambiar; Elizabeth Hutto; Patty J Ewing; Susan Piraino; Patricia Berthelette; Cathleen Sookdeo; Gloria Matthews; Donna Armentano


Archive | 1999

Chimeric adenoviral vectors for targeted gene delivery

Srinivas Shankara; Donna Armentano; Bruce L. Roberts


Journal of Virology | 1999

Novel Role for E4 Region Genes in Protection of Adenovirus Vectors from Lysis by Cytotoxic T Lymphocytes

Johanne Kaplan; Donna Armentano; Abraham Scaria; Lisa Woodworth; Sarah E. Pennington; Samuel C. Wadsworth; Alan E. Smith; Richard J. Gregory


Archive | 1999

Adenoviral vectors with modified capsid proteins

Helen Romanczuk; Donna Armentano; Catherine R. O'Riordan

Collaboration


Dive into the Donna Armentano's collaboration.

Researchain Logo
Decentralizing Knowledge